As shown, the anti-RA effect of identified compounds (quercetin, kaempferol, baicalein, beta-sitosterol, and eugenol) is partially associated with the potential target genes, including NFKBIA, IL6, and MAPK, and potential signals, including PI3K-Akt, TNF, and IL-17, indicating the interaction between multicomponents, multitargets, and multisignaling of SM treating RA. The gene discussed is AKT1; the disease is rheumatoid arthritis.